Individualizing Corticosteroid Use in Pneumonia

Overview

About this study

The objectives of this study are to identify predictors of in-hospital disease progression (prognostic enrichment), to develop an individualized treatment rule (ITR) for steroid use through advanced statistical and machine learning methods (predictive enrichment), and to evaluate an ITR-guided corticosteroid use coupled with biomarker-guided dosing strategy (optimal patient selection and dosing) in community acquired pneumonia (CAP).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Hospitalized adult (≥ 18 years) patients.
  • Community acquired pneumonia.

Exclusion Criteria:

  • Contraindications or unwillingness to use corticosteroids by patient or provider.
  • History of adrenal insufficiency, septic shock, or another absolute indication for steroid use.
  • Suspected pulmonary vasculitis or other autoimmune pulmonary disorder.
  • Positive pregnancy test
  • Comfort care.

Eligibility last updated 8/24/21. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yewande Odeyemi, M.B.B.S.

Open for enrollment

Contact information:

Yewande Odeyemi M.B.B.S.

Odeyemi.Yewande@mayo.edu

More information

Publications

Publications are currently not available